22nd Mar 2016 07:00
Notice of Results
22 March 2016
Silence Therapeutics plc
Silence Therapeutics plc, AIM: SLN, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, will announce results for the year to 31 December 2015 and trading outlook on Tuesday 5 April.
The statement will include full details on the Atu027 Phase 2a clinical results in pancreatic cancer. There will also be a detailed update on other pipeline projects, technology, IP and patent developments.
Enquiries:
Silence Therapeutics plc Ali Mortazavi, Chief Executive Officer Timothy Freeborn, Chief Financial Officer | Tel: +44 (0)20 3457 6900
|
Canaccord Genuity Limited (Nominated Adviser and Joint Broker) Dr Julian Feneley/Henry Fitzgerald-O'Connor/Emma Gabriel | Tel: +44 (0)20 7523 8350
|
Peel Hunt LLP (Joint Broker) James Steel/Dr Tom Burt/Oliver Jackson
| Tel: +44 (0)20 7418 8900 |
Media Enquiries: FTI Consulting Simon Conway/Brett Pollard/Stephanie Cuthbert | Tel: +44 (0) 20 3727 1000
|
Notes to Editors
About Silence Therapeutics plc
Our technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo.
We have developed proprietary modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutics. This allows the development of therapeutics for diseases with high unmet medical need. In 2015 Silence announced interim results from a Phase 2a pancreatic cancer trial using its compound, Atu027, in combination with gemcitabine.
Related Shares:
SLN.L